<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>More than 80 diseases are currently classified as autoimmune, with a rising prevalence throughout the world. Systemic lupus erythematosus (SLE) is classified as a systemic autoimmune disorder, but the exact pathogenesis of SLE remains elusive. Currently available treatment strategies offer only the possibility for disease remission making it essential to develop more effective and safer strategies for treatment. Recently MSCs are gaining attention as attractive therapeutic tools for autoimmune disease treatment. Special focus should be given to MSCs originated from perinatal tissues such as Wharton's jelly, as they present unique immunomodulatory properties and remarkably low immunogenicity. MSCs exert their immunomodulatory effects via direct cell-to-cell communication as well as in a paracrine manner, creating possibility to apply secretome of MSCs as an individual therapeutic tool. Although the secretome of MSCs has not yet been utilized in SLE treatment, its efficacy has been suggested in other disorders, such as multiple sclerosis or Alzheimer's disease. Regular administration of paracrine factors derived from MSCs could potentially effect in significant reduction of SLE symptoms and in maintenance of disease remission.</p>
</abstract>

More than 80 diseases are currently classified as autoimmune, with a rising prevalence throughout the world. Systemic lupus erythematosus (SLE) is classified as a systemic autoimmune disorder, but the exact pathogenesis of SLE remains elusive. Currently available treatment strategies offer only the possibility for disease remission making it essential to develop more effective and safer strategies for treatment. Recently MSCs are gaining attention as attractive therapeutic tools for autoimmune disease treatment. Special focus should be given to MSCs originated from perinatal tissues such as Wharton's jelly, as they present unique immunomodulatory properties and remarkably low immunogenicity. MSCs exert their immunomodulatory effects via direct cell-to-cell communication as well as in a paracrine manner, creating possibility to apply secretome of MSCs as an individual therapeutic tool. Although the secretome of MSCs has not yet been utilized in SLE treatment, its efficacy has been suggested in other disorders, such as multiple sclerosis or Alzheimer's disease. Regular administration of paracrine factors derived from MSCs could potentially effect in significant reduction of SLE symptoms and in maintenance of disease remission.

Mesenchymal stem cells and their secretome - candidates for safe and effective therapy for systemic lupus erythematosus

Department of Basic and Preclinical Sciences, Institute of Veterinary Medicine, Faculty of Biological and Veterinary Sciences

University Hospital and Masaryk University

Czech University of Life Sciences in Prague

Department of Clinical Sciences and Diagnostics

Institute of Veterinary Medicine, Nicolaus Copernicus University in Toruń

Department of Biomaterials and Experimental Dentistry

Medical Journal of Cell Biology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

More than 80 diseases are currently classified as autoimmune, with a rising prevalence throughout the world. Systemic lupus erythematosus (SLE) is classified...

Mesenchymal stem cells and their secretome - candidates for safe and effective therapy for systemic lupus erythematosus

Publicado en línea: 27 sept 2021

Páginas: 110 - 122

Recibido: 02 ago 2021

Aceptado: 05 sept 2021

DOI: https://doi.org/10.2478/acb-2021-0016

Palabras clave
mesenchymal stem cells, secretome, conditioned media, exosomes, SLE

© 2021 Małgorzata Popis et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

FIGURE 1

FIGURE 2

FIGURE 3

Mesenchymal stem cells and their secretome - candidates for safe and effective therapy for systemic lupus erythematosus

Publicado en línea: 27 sept 2021

Páginas: 110 - 122

Recibido: 02 ago 2021

Aceptado: 05 sept 2021

DOI: https://doi.org/10.2478/acb-2021-0016

Palabras clavemesenchymal stem cells, secretome, conditioned media, exosomes, SLE

© 2021 Małgorzata Popis et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

FIGURE 1

FIGURE 2

FIGURE 3

Palabras clave
mesenchymal stem cells, secretome, conditioned media, exosomes, SLE